Abstract
Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR ) subtypes as master regulators of lipid, lipoprotein, and glucose homeostasis, and the rapid development of parallel screening assay methods to evaluate transactivation and/or binding activity toward individual PPAR subtypes, have provided an opportunity to develop novel PPAR agonists with characteristic subtype selectivity. Such agonists are candidates for the treatment of metabolic syndrome, which includes type II diabetes, dyslipidemia, obesity, and hypertension. This review focuses on the recent literature dealing with medicinal-chemical strategies to identify PPARδ- selective agonists and PPARδ/α dual agonists. Recent progress of studies on selective modulators of PPARγM (SPPARγM) is also briefly reviewed.
Keywords: Peroxisome proliferator-activated receptor, PPAR, PPARδ agonist, PPARδ/α dual agonist, SPPARγM
Current Bioactive Compounds
Title: Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome
Volume: 2 Issue: 2
Author(s): Hiroyuki Miyachi
Affiliation:
Keywords: Peroxisome proliferator-activated receptor, PPAR, PPARδ agonist, PPARδ/α dual agonist, SPPARγM
Abstract: Improvements in our understanding of the functions of the nuclear receptor peroxisome proliferator-activated receptor (PPAR ) subtypes as master regulators of lipid, lipoprotein, and glucose homeostasis, and the rapid development of parallel screening assay methods to evaluate transactivation and/or binding activity toward individual PPAR subtypes, have provided an opportunity to develop novel PPAR agonists with characteristic subtype selectivity. Such agonists are candidates for the treatment of metabolic syndrome, which includes type II diabetes, dyslipidemia, obesity, and hypertension. This review focuses on the recent literature dealing with medicinal-chemical strategies to identify PPARδ- selective agonists and PPARδ/α dual agonists. Recent progress of studies on selective modulators of PPARγM (SPPARγM) is also briefly reviewed.
Export Options
About this article
Cite this article as:
Miyachi Hiroyuki, Recent Progress of Medicinal Chemistry Research on Peroxisome Proliferator-Activated Receptor (PPAR) Ligands for the Treatment of Metabolic Syndrome, Current Bioactive Compounds 2006; 2 (2) . https://dx.doi.org/10.2174/157340706777435176
DOI https://dx.doi.org/10.2174/157340706777435176 |
Print ISSN 1573-4072 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6646 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Atrial Tachycardias Occurring Late After Open Heart Surgery
Current Cardiology Reviews Polyunsaturated Fatty Acids in Pathological Retinal Angiogenesis
Current Nutrition & Food Science Knowledge and Perceptions Towards Cardiovascular Disease Prevention Among Patients with Type 2 Diabetes Mellitus: A Review of Current Assessments and Recommendations
Current Diabetes Reviews <i>Nigella sativa</i>, as Preventive Strategy in COVID-19
Current Traditional Medicine Improving the Efficiency and Safety of Aspirin by Complexation with the Natural Polysaccharide Arabinogalactan
Current Drug Delivery Anaemia in Diabetes: An Emerging Complication of Microvascular Disease
Current Diabetes Reviews Therapeutic Interventions to Renin-Angiotensin-Aldosterone System, and Vascular Redox State
Recent Patents on Cardiovascular Drug Discovery Cell Immunity in Coronary Artery Disease (CAD)
Current Immunology Reviews (Discontinued) Thyroid Hormones and Cardiovascular System: From Bench to Bedside
Current Drug Therapy Prediction of Disease-Related Genes Based on Hybrid Features
Current Proteomics Cardiovascular Risk in Perimenopausal Women
Current Vascular Pharmacology Kinins and Cardiovascular Diseases
Current Pharmaceutical Design Rhodiola and salidroside in the treatment of metabolic disorders
Mini-Reviews in Medicinal Chemistry Is there a Relationship between Endothelial Dysfunction of the Brachial Artery, Carotid Intima-Media Thickness and Soluble Receptors of Tumor Necrosis Factor-Alpha?
Vascular Disease Prevention (Discontinued) Study of Convolvulus pluricaulis for Antioxidant and Anticonvulsant Activity
Central Nervous System Agents in Medicinal Chemistry Chronic Hyperuricemia, Uric Acid Deposit and Cardiovascular Risk
Current Pharmaceutical Design Targeting MCP-1 to Reduce Vascular Complications of Obesity
Recent Patents on Cardiovascular Drug Discovery Pathophysiology, Diagnosis and Clinical Management of Hepatorenal Syndrome: From Classic to New Drugs
Current Vascular Pharmacology The Antiplatelet and Antithrombotic Actions of Statins
Current Pharmaceutical Design Antiangiogenic Drugs in the Treatment of Advanced Epithelial Ovarian Cancer
Anti-Cancer Agents in Medicinal Chemistry